Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Semen, L. Solovey, M. Karapinka, O. Yelisyeyeva (Lviv, Ukraine). Heart rate variability: Possible implications for management of pulmonary arterial hypertension patients. Eur Respir J 2012; 40: Suppl. 56, 970

Member's Comments

No comment yet.

Related content which might interest you: Prognostic implications of delayed heart rate recovery from maximal-incremental exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2012 - Limiting factors in exercise Year: 2012 Hospitalization in patients with pulmonary arterial hypertension: causes and outcomes Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease Source: Eur Respir Rev 2011; 20: 236-242 Year: 2011 Heart rate recovery in response to disease targeted therapy in pre-capillary pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Heart rate variability in patients with asthma and symptomatic hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 478s Year: 2003 Identification of treatment goals in paediatric pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 1616-1626 Year: 2014 Pulmonary arterial hypertension: tailoring treatment to risk in the current era Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017 Year: 2017 Challenges in pulmonary hypertension: managing the unexpected Source: Eur Respir Rev 2015; 24: 674-681 Year: 2015 Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations Source: Eur Respir Rev 2013; 22: 515-525 Year: 2013 Pulmonary arterial hypertension among elderly patients: an emerging problem? Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Impact of borderline pulmonary arterial pressure on survival Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015